PBYI Puma Biotechnology Inc

Price (delayed)

$2.86

Market cap

$128.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$180.8M

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights
Puma Biotechnology's quick ratio has increased by 31% YoY and by 19% from the previous quarter
Puma Biotechnology's debt has decreased by 4.2% YoY
The net income has plunged by 85% YoY and by 68% from the previous quarter
PBYI's EPS has dropped by 79% year-on-year and by 67% since the previous quarter

Key stats

What are the main financial stats of PBYI
Market
Shares outstanding
44.97M
Market cap
$128.62M
Enterprise value
$180.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
16.54
Price to sales (P/S)
0.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.9
Earnings
Revenue
$200.72M
EBIT
-$36.61M
EBITDA
-$26.7M
Free cash flow
-$21.91M
Per share
EPS
-$1.2
Free cash flow per share
-$0.52
Book value per share
$0.17
Revenue per share
$4.76
TBVPS
$3.24
Balance sheet
Total assets
$200.69M
Total liabilities
$193.54M
Debt
$116.09M
Equity
$7.15M
Working capital
$42.78M
Liquidity
Debt to equity
16.25
Current ratio
1.57
Quick ratio
1.35
Net debt/EBITDA
-1.95
Margins
EBITDA margin
-13.3%
Gross margin
77.6%
Net margin
-24.4%
Operating margin
-9.7%
Efficiency
Return on assets
-21.4%
Return on equity
-842.4%
Return on invested capital
-39.5%
Return on capital employed
-29.1%
Return on sales
-18.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
2.88%
1 week
-2.05%
1 month
38.16%
1 year
-68.15%
YTD
-5.92%
QTD
-0.69%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$200.72M
Gross profit
$155.74M
Operating income
-$19.5M
Net income
-$48.96M
Gross margin
77.6%
Net margin
-24.4%
Puma Biotechnology's net margin has shrunk by 149% YoY and by 112% QoQ
The net income has plunged by 85% YoY and by 68% from the previous quarter
PBYI's gross profit is down by 27% YoY and by 18% QoQ
The revenue has contracted by 26% YoY and by 21% from the previous quarter

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
P/E
N/A
P/B
16.54
P/S
0.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.9
PBYI's EPS has dropped by 79% year-on-year and by 67% since the previous quarter
Puma Biotechnology's equity has shrunk by 57% YoY
PBYI's P/B is 51% lower than its 5-year quarterly average of 32.7
PBYI's P/S is 99% below its 5-year quarterly average of 49.6 and 36% below its last 4 quarters average of 0.9
The revenue has contracted by 26% YoY and by 21% from the previous quarter

Efficiency

How efficient is Puma Biotechnology business performance
PBYI's return on sales has dropped by 189% since the previous quarter
PBYI's ROIC has shrunk by 188% YoY and by 98% QoQ
Puma Biotechnology's ROE has plunged by 165% YoY and by 135% from the previous quarter
The ROA has shrunk by 108% YoY and by 78% QoQ

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The total assets is 3.7% more than the total liabilities
The company's current ratio rose by 34% YoY and by 23% QoQ
Puma Biotechnology's quick ratio has increased by 31% YoY and by 19% from the previous quarter
Puma Biotechnology's debt to equity has surged by 134% QoQ and by 120% YoY
Puma Biotechnology's equity has shrunk by 57% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.